Measurement and Uses of Oxidative Status

• US 20160290960A1
• Filed: 06/17/2016
• Published: 10/06/2016
• Est. Priority Date: 05/18/2007
• Status: Active Grant

• Current Assignee: Caerus Biotechnologies
• Original Assignee: Aytu Bioscience, Inc.
• Inventors: Bar-Or, David, Bar-Or, Raphael
• Granted Patent: US 10,036,723 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: G01N 27/26 by investigating electrochemical variables; by using electrolysis or electrophoresis
• CPC Class Codes: G01N 27/327 Biochemical electrodes , e.g. electrical or mechanical details for in vitro measurements
• CPC Class Codes: G01N 27/4168 Oxidation-reduction potential, e.g. for chlorination of water water analysis G01N33/18
• CPC Class Codes: G01N 33/50 Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q

Abstract

The present invention provides a method of determining the overall oxidative status of a body fluid or a tissue of a patient by measuring the oxidation-reduction potential (ORP) of the body fluid or tissue. The method has been found to be useful in the diagnosis, evaluation and monitoring of patients who have suffered a trauma (such as a head injury), patients suspected of being critically-ill or who are critically ill, patients who have an infection, and patients suspected of having a myocardial infarction (MI) or who have had an MI. The method has also been found useful in monitoring and evaluating exercise performance in patients. In addition, the method has been found useful in monitoring and evaluating stored blood products and patients who will receive such a product.

Claims

1-32. -32. (canceled)

33. A method of evaluating the suitability of a stored blood product for transfusing an individual, comprising:

a. measuring the oxidation-reduction potential (ORP) of a stored blood product; and

,

b. comparing the ORP of the stored blood product with the ORP of a corresponding blood product immediately after it was obtained from a donor (fresh blood product);

wherein if the ORP of the stored blood product is significantly different than the ORP of the fresh blood product, discarding the stored blood product.

34. The method of claim 33, wherein the stored blood product has been stored for one or more days.

35. The method of claim 33, wherein the blood product is whole blood.

36. The method of claim 33, wherein the blood product is packed red blood cells.

37. The method of claim 33, wherein the ORP of the stored blood product is measured one per day during storage.

38. The method of claim 33, wherein the ORP value is measured by contacting the stored blood product with an electrode connected to a machine that provides a readout of the ORP.

39. A method of reducing side effects due to transfusion of a stored blood product, comprising:

a. measuring the oxidation-reduction potential (ORP) of the stored blood product; and

,

b. comparing the ORP of the stored blood product with the ORP of a corresponding blood product immediately after it was obtained from a donor (fresh blood product);

wherein if the ORP of the stored blood product is significantly different than the ORP of the fresh blood product, discarding the stored blood product.

40. The method of claim 39, wherein the stored blood product has been stored for one or more days.

41. The method of claim 39, wherein the blood product is whole blood.

42. The method of claim 39, wherein the blood product is packed red blood cells.

43. The method of claim 39, wherein the ORP of the stored blood product is measured one per day during storage.

44. The method of claim 39, wherein the ORP value is measured by contacting the stored blood product with an electrode connected to a machine that provides a readout of the ORP.

45. A method of identifying an individual at risk for infusion-related side effects, comprising:

a. obtaining a sample of body fluid from an individual to be infused;

b. determining the oxidation-reduction potential (ORP) value of the body fluid; and

,

c. comparing the determined ORP value with the ORP value of a corresponding body fluid from normals;

wherein if the ORP value of the body fluid from the individual is significantly higher than the ORP value of the body fluid from normals, identifying the individual at risk for developing infused-related side effects

46. The method of claim 45, wherein if the ORP value of the body fluid from the individual is significantly higher than the ORP value of the body fluid from normals, canceling the infusion.

47. The method of claim 45, wherein if the ORP value of the body fluid from the individual is significantly higher than the ORP value of the body fluid from normals, infusing the individual with a blood product containing lower levels of oxidant species.

48. The method of claim 45, wherein the stored blood product has been stored for one or more days.

49. The method of claim 45, wherein the blood product is whole blood.

50. The method of claim 45, wherein the blood product is packed red blood cells.

51. The method of claim 45, wherein the ORP value is measured by contacting the stored blood product with an electrode connected to a machine that provides a readout of the ORP.